Genmab AS

Genmab AS LT Debt/Equity

The Long-Term Debt to Equity Ratio of Genmab AS (GMAB) as of Nov 22, 2026 is 0.86. In the previous year, Long-Term Debt to Equity Ratio was 0.01 — a change of 7,669.60% (higher).

LT Debt/Equity

0.86

YoY

7,669.60%

Last updated:

Long-Term Debt to Equity Ratio of Genmab AS is 2025 0.86 . Long-Term Debt to Equity Ratio of Genmab AS was 2024 0.01 . It decreases by 7,669.60% higher compared to the previous year.

The Genmab AS LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.01 USD
Jan 1, 2025
0.86 USD
The Genmab AS LT Debt/Equity history
YEARLT Debt/EquityYoY
0.86+7,669.60%
0.01—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Long-Term Debt to Equity Ratio of Genmab AS is 0.86 in 2025.

Long-Term Debt to Equity Ratio of Genmab AS changed from 0.01 to 0.86, representing a 7,669.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Genmab AS since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Genmab AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genmab AS

All Key Metrics — Genmab AS